Stephanie and Christopher’s Story: Rare Disease and Medical Nutrition

Any parent would agree that having a child changes your world forever. Yet, having a child with a rare disease throws you not only into the role of parent but also advocate, educator, researcher, and medical provider. Those with rare diseases, and the guardians’ that care for them, have different perspectives on the world. We must, or we and those we care for will not survive.

My son Christopher was diagnosed in 2008 via new-born screening with a rare inherited metabolic condition called LCHADD. Ultimately, his body cannot break down long chain fats and use it for energy. Looking at Christopher you would never know that he has a rare disease. He is thriving academically, loves to write, play chess, make music, and compete in baseball. He enjoys magic and loves making his parents and friends laugh. In fact, his laughter is contagious.  Christopher is not thriving because his condition is “easy” to navigate. He is doing so well because he is diligent with what little things we understand about his rare disease. He takes a special medical formula daily that gives him the right kinds of fats that his body can process. He eats every two-three hours throughout the day with MCT oil drizzled on his food, so his body will not use his muscles for energy. He also works with me daily to make sure he only consumes 10g of fat through food, so fat does not gather around his heart or infiltrate his liver.

As a parent of a child with a rare disease I work really hard to understand his ever-changing condition. It is not uncommon for my husband to come home from work and find science textbooks, dictionaries and pencil/paper scattered on our living room table, as I am trying to dissect a new medical journal article. Talking with other families and looking at research are my two best avenues of preparation before doctor visits. I have met some amazing doctors, who do not resent it when I ask questions but try to work creatively with us to solve problems. A doctor told me early on, “parents of children with rare diseases quickly become the expert in their child’s disease.” It was comforting to hear a doctor recognize this but also terrifying because I did not go to school for medicine. I might wish that a medical professional could share with me all I need to know about LCHADD, but I understand that realistically when you only see 10 children a year with a specific condition, it is almost unfair to expect a doctor to be the sole source of information. We must work together as a team.

Another area of my life that has changed so much, is having to fight with the insurance company for items that my son needs to survive. When my son first arrived home from the hospital, we were told it would be too dangerous for him to breastfeed and that he needed a special medical nutrition called Lipistart. You can imagine the devastation that settled in when I learned that we were denied coverage. My husband was an Atlanta Public School teacher, and trying to pay $800 a month for medical nutrition was terrifying.  We were lucky, we were able to work with local legislators and HR to get this problem resolved, but I couldn’t shake the knowledge of what it would have been like if he was in a different job. Not all private insurance companies cover the cost of medical nutrition, and this devastates families who are already having to fight in so many different ways.  Parents and advocates have worked together for over 12 years to try and get this issue resolved for all families.  Yet, it is hard to get the right people to listen when there are so few of us. 

I still believe that people want to have compassion, want to care for others, and want to help–yet it gets harder and harder to feel this way when I see the issues of the weak and vulnerable set to the side, and that is why we need a Rare Disease Advisory Council. I may be one parent of a child with LCHADD but I am not alone in my struggle with caring for someone with a rare disease. The more people understand our journey, the better we can compassionately craft laws for the good of all.

Read Stephanie’s blog here: harryfamilyblog.blogspot.com

By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS